1. Scrip
  2. >>Drug Pricing

Astellas Positions Patients At Center Of Digital Push

‘Best Mix Of Digital And People’

 
• By Ian Haydock

While Astellas, like many other large pharma firms globally, is pursuing the adoption of digital technologies across multiple disciplines, it is aiming to keep patients at the center of its initiatives and also sees a strong need for the "best mix" of the human touch and technology. 

robot and hand
Astellas sees human-technology balance as critical in digital push • Source: Alamy

Astellas Pharma, Inc.'s over-arching goal in pursuing its own digital transformation strategy is to “turn innovative science to value for patients.” Pointing to shifting practices and new technologies in key areas including drug discovery, R&D, clinical trials and interactions with physicians, the major Japanese pharma firm's objective is, in one way or another, to keep those who ultimately receive its products at the center of these efforts.

In addition to improved value – which it defines as outcomes important to patients divided by the cost to a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.